Patents by Inventor Christine Pasero

Christine Pasero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF
    Publication number: 20240117041
    Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.
    Type: Application
    Filed: December 28, 2022
    Publication date: April 11, 2024
    Inventors: Daniel OLIVE, Christine PASERO
  • Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
    Patent number: 11945871
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: April 2, 2024
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
  • ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS
    Publication number: 20230322932
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Application
    Filed: June 1, 2023
    Publication date: October 12, 2023
    Inventors: Alemseged TRUNEH, Daniel OLIVE, Christine PASERO, Aude DE GASSART
  • ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS
    Publication number: 20230272080
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Application
    Filed: September 26, 2022
    Publication date: August 31, 2023
    Inventors: Alemseged TRUNEH, Daniel OLIVE, Christine PASERO, Aude DE GASSART
  • Antibodies having specificity for BTN2 and uses thereof
    Patent number: 11572409
    Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 7, 2023
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE, CNRS
    Inventors: Daniel Olive, Christine Pasero
  • ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF
    Publication number: 20220162305
    Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Inventors: Etienne FOUCHER, Carla CANO, Kieu Suong LE, Christine PASERO, Daniel OLIVE
  • ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS
    Publication number: 20220112289
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Application
    Filed: July 31, 2019
    Publication date: April 14, 2022
    Inventors: Alemseged TRUNEH, Daniel OLIVE, Christine PASERO, Aude DE GASSART
  • BTN3A BINDING PROTEINS AND USES THEREOF
    Publication number: 20220073619
    Abstract: It is disclosed anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of V?9/V?2 T cells. The disclosure more specifically relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their use in the manufacturing of novel drugs for use in treating cancer disorders, in particular cancers susceptible to be treated with activated ?? T cells.
    Type: Application
    Filed: December 26, 2019
    Publication date: March 10, 2022
    Inventors: Alemseged TRUNEH, Christine PASERO, René HOET, Magali COLAZET, Daniel OLIVE
  • ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF
    Publication number: 20200283519
    Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 10, 2020
    Inventors: Daniel OLIVE, Christine PASERO
  • Antagonist of the BTLA/HVEM interaction for use in therapy
    Patent number: 10005839
    Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: June 26, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Daniel Olive, Christine Pasero, Julie Gertner-Dardenne
  • COMBINATION OF A LIGAND OF HVEM AND AN IMMUNOTOXIN FOR USE IN THERAPY
    Publication number: 20160151489
    Abstract: The invention relates to i) a ligand of HVEM, and ii) an immunotoxin, as a combined preparation for simultaneous, separate or sequential use in the treatment of a solid tumor.
    Type: Application
    Filed: July 18, 2014
    Publication date: June 2, 2016
    Inventors: Daniel OLIVE, Christine PASERO
  • ANTAGONIST OF THE BTLA/HVEM INTERACTION FOR USE IN THERAPY
    Publication number: 20160122434
    Abstract: The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
    Type: Application
    Filed: May 16, 2014
    Publication date: May 5, 2016
    Applicant: Centre National de la Recherche Scientifique-CNRS
    Inventors: Daniel Olive, Julie Gertner-Dardenne, Christine Pasero
  • ANTAGONIST OF THE BTLA/HVEM INTERACTION FOR USE IN THERAPY
    Publication number: 20160090420
    Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
    Type: Application
    Filed: February 21, 2014
    Publication date: March 31, 2016
    Inventors: Daniel Olive, Christine Pasero, Julie Gertner-Dardenne
  • Ligands of HVEM for treating hematologic malignancies
    Patent number: 8318166
    Abstract: The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: November 27, 2012
    Inventors: Daniel Olive, Alemseged Truneh, Christine Pasero
  • LIGANDS OF HVEM FOR TREATING HEMATOLOGIC MALIGNANCIES AND AUTOIMMUNE DISEASES
    Publication number: 20100196386
    Abstract: The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.
    Type: Application
    Filed: June 2, 2008
    Publication date: August 5, 2010
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA MEDITERRANEE
    Inventors: Daniel Olive, Alemseged Truneh, Christine Pasero